Potential drug interaction between paclitaxel and clopidogrel.

Area of Science:

• Pharmacology
• Clinical Medicine
• Oncology

Background:

• Paclitaxel is primarily metabolized by cytochrome P450 2C8 (CYP2C8).
• Clopidogrel metabolites are known potent inhibitors of CYP2C8.
• Limited clinical data exists on the interaction between paclitaxel and clopidogrel.

Purpose of the Study:

• To investigate the potential drug interaction between paclitaxel and clopidogrel.
• To assess adverse events and discontinuation rates associated with this combination therapy.
• To evaluate the impact on neutrophil counts during co-administration.

Main Methods:

• Retrospective analysis of 8 cases involving combined paclitaxel and clopidogrel use.
• Assessment of adverse event incidence and drug discontinuation.
• Comparison of neutrophil counts before and after combination therapy.

Main Results:

• All cases (100%) experienced Grade 3 neutropenia, with 88% experiencing Grade 4.
• Febrile neutropenia occurred in 50% of patients.
• Severe adverse events requiring discontinuation occurred in 50% of cases.
• A significant reduction in neutrophil count was observed with combination therapy (P<0.01).

Conclusions:

• Co-administration of clopidogrel and paclitaxel may result in severe neutropenia due to drug interaction.
• Alternative medications should be considered to avoid this interaction.
• Close monitoring for adverse events is crucial if combination therapy is necessary.